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Introduction
Gastric cancer is the most prevalent malignancy in Korea, accounting
for 18.3% of all solid tumors [1]. Advanced gastric cancer (AGC) with
distant metastases or recurrence remains incurable, with a median survival
of 6-9 months. Metastatic gastric cancer remains a therapeutic challenge
for medical oncologists, especially for those patients with bone marrow
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Purpose
The prognosis of gastric cancer patients with bone marrow metastases is extremely poor. The
current study was conducted to evaluate the clinical outcomes of advanced gastric cancer pa-
tients with bone marrow metastases.
Materials and Methods
We retrospectively reviewed the medical records of 26 advanced gastric cancer patients with
bone marrow metastases who were treated at Soonchunhyang University Hospital between Sep-
tember 1986 and February 2009.
Results
The median age was 46 years (range, 24 to 61 years). All patients had poorly differentiated ade-
nocarcinoma, including 17 signet ring cell carcinomas. The majority of the patients had thrombo-
cytopenia, anemia, and elevated lactate dehydrogenase levels. Sixteen patients (61.5%) received
palliative chemotherapy (median, 4 cycles; range, 1 to 13 cycles). The median overall survival after
detection of bone marrow metastases for the cohort of patients was 37 days (95% confidence in-
terval, 12.5 to 61.5 days). The median overall survival after detection of bone marrow involvement
was 11 days in the best supportive care group (range, 2 to 34 days) and 121 days (range, 3 to 383
days) in the palliative chemotherapy group (p＜0.001). The causes of death were tumor progres-
sion (11 patients, 45%), brain hemorrhage (6 patients, 25%), infection (5 patients, 21%), and dis-
seminated intravascular coagulation (1 patient, 4%). There were no chemotherapy-related deaths.
Conclusion
Palliative chemotherapy could be considered in advanced gastric cancer patients with bone mar-
row metastases as a treatment option.
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metastases. Disseminated carcinomatosis of the bone marrow by solid tu-
mors frequently originated from gastric origin [2,3], although the actual
incidence of this condition is rare. The prognosis of gastric cancer with
bone marrow metastases is poor because of a rapidly deteriorating clinical
course that is often refractory to conventional treatment [4-6]. Reports on
systemic chemotherapy in gastric cancer patients with bone marrow
metastases are limited. Indeed, the variety of chemotherapy regimens or
supportive care used for these patients reflects the lack of a standard treat-
ment [7,8]. The present retrospective analysis was conducted to identify
the clinical features, treatment outcomes, and prognostic factors for sur-
vival in gastric cancer patients with bone marrow metastases. We also
compared the pre- and post-chemotherapy laboratory changes in gastric
cancer patients with bone metastases who received palliative chemother-
apy to evaluate clinical improvement, if any. 
M ater ials  and  M eth od s
1. Patients and methods 
This study retrospectively reviewed the medical records of patients with
histopathologically-proven AGC with disseminated carcinomatosis of the
bone marrow who were treated at Soonchunhyang University Hospital
between September 1986 and February 2009. From the database, 129
AGC patients were identified to have been received a bone marrow
biopsy. Of these 129 patients, 26 patients with bone marrow dissemination
pathologically-confirmed by bone marrow biopsy were identified. 
The following demographic data, disease characteristics, and treatment
parameters were reviewed: gender, age, Eastern Cooperative Oncology
Group (ECOG) performance status, tumor histology, sites of metastases
at the time bone marrow involvement was detected, time elapsed from
gastric cancer diagnosis to bone marrow involvement, and laboratory find-
ings (hemoglobin, leukocyte count, platelet count, coagulation profile,
and levels of serum lactate dehydrogenase [LDH], serum aspartate amino-
transferase [AST], alanine aminotransferase [ALT], serum alkaline phos-
phatase [ALP], albumin, sodium, calcium, total bilirubin, and uric acid).
The study was performed after approval by the Institutional Review Board
of the Soochunhyang University Hospital in Seoul, Korea.
2. Statistics
The primary endpoint of the current study was overall survival (OS),
calculated using the Kaplan-Meier product-limit method. OS was defined
as the time elapsed from the date bone marrow involvement was detected
to the date of death. Comparison of survival by univariate analysis was
estimated by the log-rank test and Cox’s proportional hazard model was
used for multivariate analysis. A p-value＜0.05 was considered to be sta-
tistically significant, but clinical parameters with a p-value＜0.10 were
included in the multivariate analysis. Laboratory variables were initially
recorded as continuous variables, and subsequently dichotomized accord-
ing to the median value of each variable.
R esults
1. Patient characteristics
The clinical characteristics of all patients are listed in Table 1. The me-
dian age was 46 years (range, 24 to 61 years) and the male-to-female ratio
was 2 : 1. The ECOG performance status was ＞2 in 12 patients (46.2%).
No. of patients (%)
Total 26
Median age (range, yr) 46 (24-61)
Gender
Male 18 (69.2)
Female  8 (30.8)
ECOG PS
0, 1 14 (53.8)
2, 3 12 (46.1)
Histological grade
Well/moderately differentiated 0 (0)
Poorlydifferentiated, only  9 (34.6)
Poorlydifferentiated/signet ring cell 17 (65.4)
Site of involvement
Bone 15 (57.7)
Lymph node 12 (46.2)
Liver 1 (3.8)
Lung 3 (11.5)
Peritoneum 1 (3.8)
Cause of bone marrow biopsy
Anemia 3 (11.5)
Thrombocytopenia 7 (26.9)
Leukoerythroblastic reaction 3 (11.5)
Anemia and thrombocytopenia 5 (19.2)
Anemia and thrombocytopenia and  5 (19.2)
leukoerythroblastic reaction
DIC 1 (3.8)
Hot uptake in bone scan                        2 (7.7)
Time of bone marrow metastases
Synchronous bone marrow metastases 12 (46.2)
Metachronous bone marrow metastases 14 (53.8)
Chemotherapy 
Yes 16 (61.5)
No 10 (38.5)
Table 1. Patient characteristics
ECOG PS, Eastern Cooperative Oncology Group performance sta-
tus; DIC, disseminated intravascular coagulation.Cancer Res Treat. 2011;43(4):244-249
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All of the patients had poorly differentiated adenocarcinoma (34.6%) or
signet ring cell adenocarcinoma (65.4%). The most common site of
metastasis was bone (57.7%), followed by lymph nodes (46.2%), lungs
(11.5%), liver (3.8%), and peritoneum (3.8%). The most common abnor-
mal laboratory findings were anemia and thrombocytopenia. Reasons for
bone marrow biopsy were thrombocytopenia, anemia, and leukoerythrob-
lastic reactions. An elevation in the serum ALP and LDH levels was a
characteristic clinical finding. The median calcium level was within the
normal range. Of 26 patients, 16 (61.5%) received palliative chemother-
apy, as follows: platinum-based (n=4), taxane-based (n=1), irinotecan-
based (n=3), and 5-fluorouracil-based (n=8). 
2. Response and survival
Sixteen patients (61.5%) received palliative chemotherapy, with a me-
dian of 4 cycles per patient (range, 1 to 13 cycles). One patient discontin-
ued treatment and was lost to follow-up, so 15 patients were analyzed in
this study. The objective response rate was 33.3%; 5 patients (33.3%) had
partial responses, 5 patients (33.3%) had stable disease, and 3 patients
(20.0%) had progressive disease. The disease control rate was 66.6%
(Table 2). The median survival time in patients with gastric cancer and
bone marrow metastases was 37 days (95% confidence interval [CI], 12.5
to 61.5 days). The median survival time was 11 days in the supportive
care group (range, 2 to 34 days) and 121 days (range, 3 to 383 days) in
the palliative chemotherapy group (p＜0.001) (Figs. 1 and 2). Patients
died of tumor progression (11 patients, 45%), brain hemorrhage (6 pa-
tients, 25%), infection (5 patients, 21%), and disseminated intravascular
coagulation (1 patient, 4%). There were no chemotherapy-related deaths.
3. Laboratory changes before and after chemotherapy
White blood cell (WBC) and platelet counts, hemoglobin, prothrombin
time (PT), and activated partial thromboplastin time (aPTT) were checked
at every cycle of chemotherapy; the median post-chemotherapy laboratory
values were obtained after 3 cycles of chemotherapy. The WBC and
platelet counts were increased in the chemotherapy group, but hemoglo-
bin, PT, and aPTT values did not change significantly (Table 3). 
4. Prognostic factor analysis
Based on univariate analyses, WBC＞8,000/ʼL (p＜0.02) and sup-
portive care (p＜0.001) had adverse effects on survival (Table 4). Clinical
parameters with a p-value＜0.10 (WBC＞8,000/ʼL, ALT＞31 IU/L, and
supportive care) and universal parameters, such as ECOG and age, were
included in the multivariate analysis. Using the forward Cox regression
model, statistically significant poor prognostic factors for survival were
supportive care (p＜0.001; relative risk [RR], 18.93; 95% confidence in-
terval [CI], 2.78 to 69.72) and an ALT＞31 IU/L (p＜0.023; RR, 16.68;
95% CI, 1.18 to 8.88) (Table 5).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; PT, prothrombin time;
aPTT, activated partial thromboplastin time.
Table 3. Laboratory findings at the time of diagnosis
Pre-chemotherapy   Post-chemotherapy 
Lab value
Median                   Range Median          Range     
White blood cells (/ﾵL) 8,200 2,000-53,000 4,850 2,600-11,750
Hemoglobin (g/dL) 8.9 5.0-13.6 8.9 5.0-10.2
Platelets (/ﾵL) 56,000 16,000-411,000 109,500 27,000-265,000
AST (IU/L) 53 16-731
ALT (IU/L) 27 9-256
ALP (IU/L) 467 30-2,352
LDH (IU/L) 1,330 279-2,590
Calcium (mg/L) 8.6 7.8-12.5
Albumin (g/dL) 3.4 2.7-4.4
Sodium (mmol/L) 138 128-145
PT (sec) 14.6 10.5-20.4 13.1 11.6-15.6
aPTT (sec) 29.3 15.6-43.8 29.0 22.3-40.1
Table 2. Response rate of chemotherapy
Best response No. (%)
Total 15
Complete response 0 (0)
Partial response 5 (33.3)
Stable disease 5 (33.3) 
Progressive disease 3 (20.0) 
Not available 2 (13.3) Ji Yeon Kwon, Bone Marrow Metastases
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Table 4. Univariate analysis of prognostic factors for survival 
Univariate analysis 
No. of patients (%) 
MST days 95% confidence interval          p-value                       
Age (yr)
≤40 8 (32.0) 11 0.0-33.2 0.16
＞40 17 (68.0) 51 0.0-158.1
Gender
Male 17 (68.0) 34 0.4-67.6
Female 8 (32.0) 37 0.0-82.7 0.59
ECOG PS
0, 1 14 (56.0) 31 0.0-65.8
2, 3 11 (44.0) 51 0.0-150.3 0.20
Histology
Signet ring cell (+) 9 (36.0) 60 12.5-108.7
Signet ring cell (-) 16 (64.0) 110 47.8-173.3 0.30
Chemotherapy
Yes 15 (60.0) 121 94.7-147.3
No 10 (40.0) 11 9.5-12.5 0.00
White blood cells (/ﾵL)
≤8,000 11 (47.8) 158 80.0-235.8 0.02
＞8,000 12 (52.2) 46 7.5-85.6
Hemoglobin (g/dL)
≤8.9 14 (60.9) 37 0.0-97.5 0.74
＞8.9  9 (39.1) 51 0.0-109.4
Platelets (/ﾵL)
≤56,000 13 (56.5) 51 5.2-96.8 0.76
＞56,000 10 (43.5) 31 0.0-152.2
PT (sec)
≤14.6 11 (47.8) 118 21.4-214.6 0.17
＞14.6 12 (52.2) 11 9.3-12.7
aPTT (sec)
≤29.3 11 (50.0) 37 0.0-152.4 0.42
＞29.3  11 (50.0) 51 0.0-38.6
AST (IU/L)
≤53 13 (56.5) 51 0.0-154.3 0.89
＞53 10 (43.5) 37 0.0-100.5
ALT (IU/L)
≤31 13 (56.5) 118 12.3-223.7 0.06
＞31 10 (43.5) 11 19.9-82.1
ALP (IU/L)
≤500 10 (45.5) 31 0.0-71.3 0.24
＞500 12 (54.5) 106 6.0-206.4
LDH (IU/L)
≤1,300  11 (50.0) 106 0.0-213.9 0.93
＞1,300 11 (50.0) 37 9.3-92.7
Sodium (mmol/L)
≤138 13 (56.5) 18 0.0-66.1 0.47
＞138 10 (43.5) 51 0.0-176.5
Albumin (g/dL)
≤3.4 12 (52.2) 37 0.0-185.1 0.56
＞3.4  11 (47.8) 51 16.6-85.4
MST, median survival time; ECOG PS, Eastern Cooperative Oncology Group performance status; PT, prothrombin time; aPTT, activated partial
thromboplastin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase.Cancer Res Treat. 2011;43(4):244-249
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Discussion
When compared with supportive care, chemotherapy for advanced or
recurrent gastric cancer has survival benefits [9,10]. The incidence of gas-
tric cancer patients with bone marrow metastases is low. As a result, the
clinical features and optimal treatment options for such patients have yet
to be established. Using retrospective single center data, Kim et al. [11]
reported the prevalence of AGC with bone marrow metastases, as con-
firmed by bone marrow biopsy, to be 0.024%. In that study, the significant
poor prognostic factors for survival were serum Na＜133 mmol/L, lung
metastases, and peritoneal seeding. Because this subset of patients was
excluded from clinical trials due to inadequate laboratory findings or other
causes, little outcome data are available on the clinical features of this
group of patients or the optimal chemotherapy regimens. 
The aim of the current study was to analyze the clinical features, treat-
ment outcomes, and prognostic factors for survival in gastric cancer pa-
tients with bone marrow metastases. The clinical features of such patients
include a younger age, an elevation in the level of serum ALP and/or LDH,
extensive bone metastases, low incidence of hypercalcemia, and histologic
type gastric cancer (signet ring cell carcinoma or poorly differentiated
adenocarcinoma) [7,11]. In the present study, the majority of the patients
were characterized by young age (median age, 46 years), poorly differ-
entiated adenocarcinoma (100%), elevated LDH (1,330 IU/L; normal
range, 279 to 2,590 IU/L), and elevated ALP (467 IU/L; range, 30 to 2,352
IU/L). The clinical factors predicting survival based on multivariate analy-
sis were chemotherapy and elevated ALT levels. However, the numbers
of analyzed cases were too small to derive any definite conclusion about
the association of chemotherapy with survival in patients with bone mar-
row metastases.
In the present study, the median survival for the entire cohort of patients
was 37 days (95% CI, 12.5 to 61.5 days), which is consistent with the
findings from previous studies [7,11]. Thus, the prognosis of AGC patients
with bone marrow metastases is poor, regardless of the treatment, con-
sidering that the median survival for patients with metastatic or inoperable
AGC is 6-9 months. 
The median survival time was 11 days in the supportive care group
(range, 2 to 34 days) and 121 days (range, 3 to 383 days) in the palliative
chemotherapy group (p＜0.001). Kusumoto et al. [7] studied nine patients
with gastric cancer and diffuse bone marrow metastases; the median sur-
vival time was 187ﾱ62 days in the chemotherapy group (n=4) and 55ﾱ42
days in the supportive group (p＜0.02). Similarly, Kim et al. [11] studied
39 patients with gastric cancer and bone marrow metastases; the median
survival from the time of detection of bone marrow involvement was 44
days (range, 2 to 252 days) in all patients, 20 days (range, 2 to 137 days)
in the best supportive group, and 67 days (range, 5 to 252 days) in the pal-
liative chemotherapy group (p=0.026). Although limited by a relatively
small number of patients and the retrospective design of the study, the sur-
vival period of the patients treated with chemotherapy was significantly
longer than the patients who did not receive chemotherapy. The results
suggest that palliative chemotherapy should be considered as a method
of treatment to improve the prognosis of gastric cancer patients with bone
Fig. 1.  Kaplan-Meier estimates of overall survival (OS) in all 
patients.  
Fig. 2. Kaplan-Meier estimates of overall survival: chemo-therapy
group vs. supportive care group.  
Table 5. Multivariate cox regression analyses 
p-value             Relative risk (exp. B) 95% confidence interval       
Supportive care group (without chemotherapy)   ＜0.001 18.93 2.78-69.72
Alanine aminotransferase (＞31 IU/L) 0.023 16.68 1.18-8.88Ji Yeon Kwon, Bone Marrow Metastases
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marrow metastases. However, due to the lack of prospective studies for
gastric cancer patients with bone marrow metastases, an optimal regimen
of chemotherapy is not known. 
In the present study, the laboratory findings at the time of detection of
bone metastases were as follows: median WBC, 8,200/ʼL (range, 2,000
to 5,350/ʼL); median hemoglobin, 8.9 g/dL (range, 5.0 to 13.6 g/dL); and
platelet count, 56,000/ʼL (range, 16,000 to 411,000/ʼL). Thirty percent
of patients had inadequate laboratory findings for cytotoxic chemothera-
pies. Nevertheless, the most common cause of death in patients with gas-
tric cancer and bone marrow metastases was disease progression, not
chemotherapy-related hematologic toxicities. But, it is difficult to deter-
mine whether the intensity of cytotoxic chemotherapy should be increased
to prolong patient survival or lowered to avoid toxicity. Thrombocytopenia
(80.8%) was the most common peripheral blood finding. At the time of
diagnosis with AGC, clinicians should suspect bone marrow metastases
in gastric cancer patients and consider a bone marrow biopsy if patients
present with prominent thrombocytopenia. In comparing the laboratory
changes before and after chemotherapy, an increased WBC count and he-
moglobin level were statistically insignificant, but thrombocytopenia im-
proved significantly with better outcomes, such as reducing the need for
platelet transfusion. 
The optimal treatment strategy for AGC patients with bone marrow
metastases remains to be determined due to the lack of prospective studies.
Based on our analysis, chemotherapy in gastric cancer patients with bone
marrow metastases seems to be efficacious in terms of OS. Given these
considerations, our next step will be to a prospective investigation of
chemotherapy in the treatment of AGC patients with bone marrow metas-
tases.
C onclusion
This study suggests that palliative chemotherapy could be considered
as a treatment option in AGC patients with bone marrow metastases. The
optimal treatment modality needs to be defined in prospective trials for
this subset of patients. 
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